We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
The European Medicines Agency (EMEA) has imposed sweeping restrictions on Cox-2 inhibitor drugs, which include labeling changes and warnings for the controversial drug class.